Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Invertase Peptide
- Development stage
- Preclinical
- Lead developer
- Dandu Biosciences
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Peptides
01
Overview
Invertase Peptide is an enzyme-based therapeutic candidate being developed by Dandu Biosciences. Invertase, also known as beta-fructofuranosidase, is an enzyme that catalyzes the hydrolysis of sucrose into its constituent monosaccharides, glucose and fructose. While Dandu Biosciences has not publicly disclosed the specific therapeutic indication for this candidate, it is categorized within their enzyme and recombinant peptide pipeline. The program is currently in the analytical transfer stage, which typically involves the transition of analytical methods between laboratories or into a production environment during preclinical development.
Beyond the preview
Go deeper on Invertase Peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invertase Peptide.